February 2008

PRESIDENT’S MESSAGE

As President of Anavex Life Sciences Corp. (OTCBB: AVXL), I am pleased that you are taking the time to learn more about our company, its rich drug development program and its proprietary drug discovery platform.

ANAVEX has a robust pipeline of drugs in development targeting numerous cancers, including that of the breast, colon, prostate and lung, as well as diseases of the central nervous system, such as Alzheimer’s, depression and epilepsy.  The ANAVEX drug candidates are unique in that they offer disease-modifying potential, while many drugs currently available only treat underlying symptoms, not the disease itself.

Our SIGMACEPTOR™ drug discovery platform is critical to our success.  It continues to generate new drug candidates with unique modes of action.  In doing so, the SIGMACEPTOR™ platform makes use of a new class of molecules known as sigma ligands, which impact the origin and/or development of a disease.  This novel approach offers significant promise for the treatment of a number of devastating medical conditions and underscores the significant growth potential for ANAVEX. 

As a result of our proprietary platform, drug candidates to treat three diseases are currently in late pre-clinical stage: ANAVEX 1-41 (Alzheimer’s), ANAVEX 2-73 and its optimized derivative ANAVEX 19-144 (epilepsy), and ANAVEX 7-1037 (colorectal cancer and other types of solid tumors).  Results from these pre-clinical tests have been positive and we expect to file Investigational New Drug applications with the U.S. Food and Drug Administration for the top three lead candidates in 2008.  We believe that our Alzheimer’s compound will be the first to reach Phase 1 clinical trials and expect to commence human testing later this year or in early 2009.

Collaborations are also extremely important to ANAVEX.  We are proud to have strong partnerships with renowned European research and academic institutions such as Montpellier University, Louis Pasteur University, and the Academy of Athens’ Institute of Biomedical Research.  These partnerships make it possible for ANAVEX to limit its R&D costs while maintaining firm control of its research efforts and intellectual property.  This year we also plan to expand our collaborations beyond Europe to include major American research and academic institutions.

ANAVEX is led by a superb management team and Board of Directors with extensive experience in the pharmaceutical sector, the securities industry, business modeling and analysis, and public company administration.  We are confident that our team will build on the momentum it has created and continue to grow and develop the company as we work to combat the world’s most devastating diseases.

With that, I invite you to conduct further research into Anavex Life Sciences Corp. and to contact us if you have any questions.  If you are already a shareholder, we thank you for your loyalty and support.  It is our hope that you will continue to participate in the ongoing success of Anavex Life Sciences Corp.

Sincerely,

Harvey Lalach
President